Search Results

Vapotherm, Inc., announced first quarter 2024 financial results and related highlights.

Vapotherm, Inc., announced that it has signed a definitive merger agreement with a newly-formed entity organized and funded by an affiliate of Perceptive Advisors, LLC, a leading health care investment firm, and its Perceptive Discovery Fund.

Vapotherm, Inc., announced the debut of its Access365™ Home Ventilation Solution at the upcoming MEDTRADE conference.

Vapotherm, Inc. (OTCQX: VAPO), (“Vapotherm” or the “Company”), today announced fourth quarter and fiscal year 2023 financial results and related highlights.

Onymos, developer of the world’s first Features-as-a-Service platform, and Vapotherm, Inc. (OTCQX: VAPO), (“Vapotherm”), a global medical technology company whose proprietary high-velocity therapy® products treat patients of all ages suffering from respiratory distress, today announced the formation of a development and commercialization partnership.

Vapotherm, Inc., a global medical technology company specializing in the development and commercialization of its proprietary Vapotherm high-velocity therapy® products for patients of all ages experiencing respiratory distress, is pleased to announce the regulatory approval of the HVT 2.0 system in Brazil.

Vapotherm, Inc., announced third quarter 2023 financial results and related highlights.

Vapotherm, Inc., announced that it will release financial results for the third quarter of 2023 after the close of trading on Wednesday, November 8, 2023.

Vapotherm, Inc., announced it has received notice that the New York Stock Exchange has determined to suspend trading of – and commence proceedings to delist – shares of the Company’s common stock, effective immediately.